The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other conditions with newer weight-loss drugs.

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced Parkinson's disease, Supernus Pharmaceuticals announced on Tuesday. The wearable device is the first subcutaneous apomorphine infusion device for Parkinson's and provides continuous treatment during the day, Supernus noted.

A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people with Parkinson’s disease, according to a new study. Researchers conducted a double-blind,

Semaglutide, the drug used in Ozempic, has been linked to lowering the risk of Alzheimer's disease in the past. So, it was natural for the scientists to be hopeful when they tested the possibility of an Ozempic-like drug to improve Parkinson's disease symptoms,

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease progression over 96 weeks of treatment, according to a phase 3 study published in The Lancet.

I wouldn’t do another study like this unless you learn what is the target,” Dr. David Standaert, a Parkinson’s researcher at the University of Alabama at Birmingham, told